Yuma Nonomiya^*, Takashi Yokokawa^†, Kazuyoshi Kawakami^†, Kazuo Kobayashi^†, Takeshi Aoyama^†, Tomomi Takiguchi^†, Takahito Sugisaki^†, Kenichi Suzuki^†, Mitsukuni Suenaga^‡, Takeru Wakatsuki^‡, Kensei Yamaguchi^‡, Yoshikazu Sugimoto^*, Toshihiro Hama^†

Oncology Research, Vol.27, No.5, pp. 551-556, 2019, DOI:10.3727/096504018X15291727589740

Abstract Regorafenib is a multikinase inhibitor for the treatment of metastatic colorectal cancer. Regorafenib-induced hand–foot skin reaction (HFSR) is a common side effect during treatment. The reported frequency of HFSR was 80% (grade 3: 28%) in the Japanese subpopulation in the CORRECT trial; however, more detailed data regarding HFSR in terms of onset and sites of susceptibility are unclear. Additionally, the risk factors for regorafenib-induced severe HFSR are unknown. The aim of this study was to compare HFSR between the hands and feet and identify preexisting risk factors for severe HFSR in Japanese patients receiving regorafenib.… More >

Kazuyoshi Kawakami^*, Takashi Yokokawa^*, Kazuo Kobayashi^*, Takahito Sugisaki^*, Kenichi Suzuki^*, Mitsukuni Suenaga^†, Kensei Yamaguchi^†, Ayaka Inoue^‡, Yoshiaki Machida^‡, Toshiharu Yamaguchi^†, Toshihiro Hama^*

Oncology Research, Vol.25, No.9, pp. 1625-1631, 2017, DOI:10.3727/096504017X15012905098071

Abstract Adherence has become an important issue in modern oncology treatment. Most studies have included heterogeneous target tumor types, regimens, and therapy settings. Our study focused on capecitabine during capecitabine plus oxaliplatin (XELOX) treatment as an adjuvant therapy for colorectal cancer. The main aims of this study were to evaluate real-life adherence to capecitabine and to investigate candidate factors that might decrease adherence. We studied 338 consecutive patients who received XELOX treatment between December 1, 2011, and April 30, 2015, at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research. Our study assessed adherence… More >